anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
There is provided a formulation comprising: (a) a plurality of particles having a weight-, number-, or volume-based mean diameter that is between about 10 nm and about 700 μm, which particles comprise solid cores coated with a coating comprising zinc oxide; and (b) an aqueous carrier system, in which said coated particles are suspended, which carrier system comprises: (i) an injectable compound that is capable of reacting with zinc and, in doing so, reduces or prevents the reaction of zinc with water to form zinc hydroxide (such as a compound that provides a source of counter-ions that are capable of forming a compound (e.g. a salt) with zinc that is essentially insoluble in said aqueous media); and (ii) an injectable (e.g. intramuscularly- and/or subcutaneously-injectable) buffer system that either: 1. is essentially incapable of forming a compound (e.g. a salt) with zinc; or 2. comprises a source of counter-ions that are capable of forming a compound (e.g. a salt) with zinc that is more soluble in said aqueous media than zinc hydroxide. Said solid cores preferably comprise one of more biologically active agents and said coated particles are preferably synthesized via a gas phase coating technique, such as atomic layer deposition. Formulations comprising biologically active agents may provide for stable injectable aqueous suspensions at physiologically-acceptable pHs, which are capable of forming a depot after injection (e.g. intramuscularly or subcutaneously) that does not exhibit a burst effect.
Although immunotherapy is relatively effective in treating hematological malignancies, their efficacy against solid tumors is still suboptimal or even noneffective presently. Compared to hematological cancers, solid tumors exhibit strikingly different immunosuppressive microenvironment, severely deteriorating the efficacy of immunotherapy: (1) chemical features such as hypoxia and mild acidity suppress the activity of immune cells, (2) the pro-tumorigenic domestication of immune cells in the microenvironment within the solid tumors further undermines the effectiveness of immunotherapy, and (3) the dense physical barrier of solid tumor tissues prevents the effective intratumoral infiltration and contact killing of active immune cells. Therefore, we believe that reversing the immunosuppressive microenvironment are of critical priority for the immunotherapy against solid tumors. Due to their unique morphologies, structures, and compositions, nanomedicines have become powerful tools for achieving this goal. In this Perspective, we will first briefly introduce the immunosuppressive microenvironment of solid tumors and then summarize the most recent progresses in nanomedicine-based immunotherapy for solid tumors by remodeling tumor immune-microenvironment in a comprehensive manner. It is highly expected that this Perspective will aid in advancing immunotherapy against solid tumors, and we are highly optimistic on the future development in this burgeoning field.
The present invention relates to an anti-tumor bis-dicarboxylic diamino platinum derivative disclosed in the following formula [I]. In the formula (I), R1 and R2 are defined in the specification. The present invention also relates to a preparation method for the derivate in the formula (I) and anti-tumor medicine combination containing the derivate in the formula (I). The present invention has the advantages of low toxicity, broad anti-cancer spectrum, high anticancer activity, high water solubility, high stability of aqueous solution, etc. and can alternatively kill cancer cells but does not damage normal cells. The present invention is a novel safe and effective anti-cancer medicine.
Action Observation (AO) therapy regimen will include watching a 6 minute video of another person completing a specified functional task (Putting on a shirt, pick up a sandwich and bring to mouth, eat food with a spoon, or cut meat with knife and fork). Subjects will be instructed to carefully watch the AO video and prepare to physically perform the task immediately after observing the video. The Repetitive Task Practice (RTP) therapy regimen emphasizes repeated physical performance with the hemiplegic upper limb for 24 minutes of a specified functional task that is matched to the AO recording. The AO + RTP regimens will be repeated for a total of 60 minutes. Each Subject will complete a Home Exercise Program (HEP) will include practicing components and movement patterns of the functional task that was difficult for the patient to perform during RTP intervention for 30 minutes each day outside of scheduled intervention sessions.
Participants have sessions of relaxation and electrostimulation therapy during 20 minutes. They will receive two sessions in the same week, one of electrostimulation therapy and another of relaxation. Also, participants complete a set of questionnaires at the following times: pre-test (T0), post-test (T1), and 1-month post-intervention follow-up (T2).
Medullary thyroid cancer (MTC) is a neuroendocrine tumor originating from thyroid C cells. Neuroendocrine tumors have been demonstrated to express somatostatin receptors as well as mTOR pathway. The somatostatin analogues now available (octreotide and lanreotide) act preferentially through the somatostatin receptor subtype 2 (sst2). In MTC, these compounds have been reported to exert anti-secretive effects on calcitonin but no anti-proliferative effects.SOM230 (pasireotide) is a new somatostatin analogue showing a peculiar binding profile with high affinity for sst1, sst2, sst3, sst5. Preliminary data show SOM230 to be effective in a phase II study on patients with metastatic carcinoid. RAD001 (everolimus) is a novel agent that interacts with mTOR. It was demonstrated to inhibit tumor growth in neuroendocrine tumor cell lines. Some clinical trials have explored the efficacy of a combined therapy with RAD001 plus octreotide in patients with digestive neuroendocrine tumors, highlighting encouraging results in term of tumor control.In particular, octreotide and RAD001 seem to show a synergistic activity in inhibiting neuroendocrine tumor proliferation.
Renal ischemia-reperfusion (I/R) can be precipitated by multiple clinical situations that lead to impaired renal function and associated mortality. The resulting tubular cell damage is the outcome of complex disorders including, an inflammatory process with an overproduction of cytokines. Here, diacerein (DIA), an inhibitor of proinflammatory cytokine interleukin-1 beta (IL-1β), was investigated against renal I/R in rats. DIA was orally administrated (50 mg/kg/day) for ten days before bilateral ischemia for 45 min with subsequent 2 hr. reperfusion. Interestingly, DIA alleviated the renal dysfunction and histopathological damage in the renal tissues. Pretreatment with DIA corrected the oxidative imbalance by prevented reduction in antioxidant levels of GSH and SOD, while it decreased the elevation of the oxidative marker, MDA. In addition, DIA downregulated IL-1β and TNF-α expression in the renal tissues. Consequent to inhibition of the oxidative stress and inflammatory cascades, DIA inhibited the phosphorylation of p38 mitogen-activated protein kinase (p38 MAPK). Therefore, downstream targets for p38 MAPK were also inhibited via DIA which prevented further increases of inflammatory cytokines and the apoptotic marker, caspase-3. Collectively, this study revealed the renoprotective role of DIA for renal I/R and highlighted the role of p38 MAPK encountered in its therapeutic application in renal disease.
Well-controlled type 1 diabetes (T1DM) is characterized by inflammation and endothelial dysfunction, thus constituting a suitable model of subclinical cardiovascular disease (CVD). miR-199b-5p overexpression in murine CVD has shown proatherosclerotic effects. We hypothesized that miR-199b-5p would be overexpressed in subclinical CVD yet downregulated following metformin therapy. Inflammatory and vascular markers were measured in 29 individuals with T1DM and 20 matched healthy controls (HCs). miR-199b-5p expression in CFU-Hill's colonies was analyzed from each study group, and correlations with inflammatory/vascular health indices were evaluated. Significant upregulation of miR-199b-5p was observed in T1DM, which was significantly downregulated by metformin. miR-199b-5p correlated positively with vascular endothelial growth factor-D and c-reactive protein (CRP: nonsignificant). ROC analysis determined miR-199b-5p to define subclinical CVD by discriminating between HCs and T1DM individuals. ROC analyses of HbA1c and CRP showed that the upregulation of miR-199b-5p in T1DM individuals defined subclinical CVD at HbA1c > 44.25 mmol and CRP > 4.35 × 106 pg/mL. Ingenuity pathway analysis predicted miR-199b-5p to inhibit the target genes SIRT1, ETS1, and JAG1. Metformin was predicted to downregulate miR-199b-5p via NFATC2 and STAT3 and reverse its downstream effects. This study validated the antiangiogenic properties of miR-199b-5p and substantiated miR-199b-5p overexpression as a biomarker of subclinical CVD. The downregulation of miR-199b-5p by metformin confirmed its cardio-protective effect.
The recommended starting dose of Testosterone Topical Solution is 60 mg of testosterone (2 pump actuations) applied once daily.

To ensure proper dosing, serum testosterone concentrations should be measured after initiation of therapy to ensure that the desired concentrations (300 ng/dL to 1050 ng/dL) are achieved. The Testosterone Topical Solution dose can be adjusted based on the serum testosterone concentration from a single blood draw 2 to 8 hours after applying Testosterone Topical Solution and at least 14 days after starting treatment or following dose adjustment.

If the measured serum testosterone concentration is below 300 ng/dL, the daily testosterone dose may be increased from 60 mg (2 pump actuations) to 90 mg (3 pump actuations) or from 90 mg to 120 mg (4 pump actuations). If the serum testosterone concentration exceeds 1050 ng/dL, the daily testosterone dose should be decreased from 60 mg (2 pump actuations) to 30 mg (1 pump actuation) as instructed by a physician. If the serum testosterone concentration consistently exceeds 1050 ng/dL at the lowest daily dose of 30 mg (1 pump actuation), Testosterone Topical Solution therapy should be discontinued.

The application site and dose of Testosterone Topical Solution are not interchangeable with other topical testosterone products.
OBJECTIVES: To investigate the most common concomitant symptoms and the urgent demand of solution in the breast cancer patients undergoing postoperative endocrine treatment, as well as the acceptance and expectation of acupuncture in the patients so as to provide the scientific data for promoting the application of acupuncture in the breast cancer patients.
METHODS: Breast cancer patients treated in Tianjin Medical University Cancer Institute and Hospital from January 2022 to March 2023 were randomly selected as the subjects. Using "questionnaire star" website, the questionnaire was conducted to investigate the relevant concomitant symptoms of the patients in postoperative endocrine treatment and the questions related to acupuncture treatment.
RESULTS: In this study, 229 questionnaires were distributed and 211 valid ones were collected, with the response rate of 92.1%. Among these patients, the first three common symptoms were sleep disorders (157 cases, 74.4%), hot flashes (138 cases, 65.4%) and joint / muscle pain (118 cases, 55.9%);the top three symptoms to be solved the most urgently were sleep disorders (131 cases, 62.1%), joint / muscle pain (62 cases, 29.4%) and hot flashes (45 cases, 21.3%). 79.1% of the patients (167 cases) were willing to receive acupuncture treatment because of the high expectations on its potential effect (93%). 20.9% of them (44 cases) refused acupuncture because they were worried not to be treated by the experienced physicians of TCM (52%) or afraid of needling feelings (48%). The average expectation value of acupuncture treatment was 4.02 points (5 points for the total score) among patients willing to receive acupuncture treatment. The main purposes of receiring acupuncture for the patients undergoing endocrine treatment were to strengthen the immune function (92%), reduce the adverse reactions (83%), and improve the physical condition (75%), et al.
CONCLUSIONS: Sleep disorder is one of the most concerned symptoms in endocrine treatment for the patients after breast cancer surgery. The patients highly expect for acupuncture treatment even though some patients dislike the needling sensation. How to provide the acceptable and high-quality acupuncture services for cancer patients will be one of the major directions of acupuncture research in the future.
Calm measurement of blood pressure and heart rate simultaneously by smartwatch and vital signs monitor. Each participant will undergo this measurement a total of 6 times.
<P>PROBLEM TO BE SOLVED: To produce a protein having a modified glycosylation pattern to generate improved treatment value.  <P>SOLUTION: A host cell is manipulated to express at least one nucleic acid encoding a glycoprotein-modified glycosyltransferase in a regulated level. In one specific embodiment, the host cell is manipulated to express the favorable region of glycoprotein-modified glycosyltransferase activity to increase an N-bond type complex oligosaccharide having bisecting GlcNAc. In another embodiment, the method for producing a modified glycoform of a glycoprotein such as an antibody (the whole antibody molecule, an antibody fragment or a fusion protein that includes a region equivalent to the Fc region of an immunoglobulin, with enhanced Fc-mediated cytotoxicity) is provided. The glycoprotein is thus produced.  <P>COPYRIGHT: (C)2009,JPO&INPIT
Kübler-Ross's five-stage model of death and dying-denial, anger, bargaining, depression, and acceptance-is one of the most popular theoretical models to come out of the 20th century. How did an obscure theory of the dying process come to dominate our understanding of emotional processes altogether? Building on previous work in the sociology of knowledge, I analyze the diffusion and institutionalization of Kübler-Ross's five-stage model in scientific and journalistic fields. Specifically, I analyze all 3216 citations of Kübler-Ross in the New York Times and the Web of Science database using qualitative and quantitative text analysis. I demonstrate how early scientific interest and commercial promotion led to adoption in popular culture, and document how the five-stage model expanded to cover everything from rent prices to COVID-19. I also argue that renewed interest in Kübler-Ross's work may signal contemporary attempts to mine the tradition for meaningful understandings of death and dying.
The present invention relates to a process for producing polymer microparticles laden with at least one aroma chemical, which comprises i. dissolving the at least one aroma chemical and an organic polymer composition, which contains at least one polyester as a main constituent, in a volatile organic solvent having a boiling point lower than the boiling point of the aroma chemical and having a solubility in water of at most 100 g/L at 20°C and 1013 mbar, whereby a solution of the aroma chemical and the organic polymer composition is obtained; ii. emulsifiying the solution obtained in step i. in an aqueous medium containing at least one dispersant; iii. removing the volatile organic solvent from the emulsion by evaporation at a temperature of below 80°C and at a pressure below atmospheric pressure, whereby an aqueous suspension of the laden polymer microparticles is obtained. The present invention also relates to microparticles laden with an aroma chemcial, obtainable by the process described herein and to products containing the microparticle composition. The compositions are useful as additives for imparting a scent or flavour to a product. The compositions allow for controlled release of the aroma chemicals.
PROBLEM TO BE SOLVED: To obtain a new polypeptide consisting of a secretory cell function- regulatory protein having a specific amino acid sequence, and usable in e.g. the diagnoses, treatments and prophylaxes of osteopathy/arthropathy and pathologic neovascularization, in screening compounds capable of regulating the activity of the new polypeptide. SOLUTION: This new polypeptide is a new secretory cell function-regulative protein consisting of a polypeptide (amide, ester, salt) containing an amino acid sequence identical or substantially identical with an amino acid sequence of the formula, the polypeptide or the corresponding DNA encoding the polypeptide being usable in e.g. the diagnoses, treatments and prophylaxes of osteopathy/arthropathy and pathologic neovasucularization, and also useful as e.g. a reagent for screening compounds capable of promoting or ihibiting the activity of this polypeptide. This polypeptide is obtained by the following procedure: using human fetal brain-derived poly(A)+RNA, 5'RACE (rapid amplification of cDNA end) and 3'RACE are conducted to effect cloning, the resultant gene is integrated into a vector and then expressed in host cells.
A gamified pharmaceutical packaging, dispensing system, and methodology is disclosed. The innovative gamified smart packaging system and methodology provides a variety of incentives to patients and relevant teams to take their medications, on time, and at the correct dosage. The system comprises monitored pharmaceutical dispensing devices that communicate with a plurality of compute devices, or smartphones. Each time the patient dispenses the medicine from the dispensing device, a signal is transmitted to the compute device. Upon receiving the signal, the compute device records the dispensing event, calculates a specific "score" for that event, and reports the patient's cumulative "score" of successfully dispensing the medicine. If a dispensing event signal is not received in a timely fashion, the system sends a prompt to the patient to take their medication. Accumulating points by properly taking the prescribed medication allows the patient and/or team to be eligible to receive various benefits.
The present invention relates to a veterinary wound dressing. The wound dressing comprises a standard veterinary bandage of the type normally employed to cover a wound. The bandage includes an outer surface and a wound-facing surface. In a first embodiment of the invention, a layer of fabric or a polymeric film containing an animal repellant substance is affixed to the outer surface of the bandage during the manufacturing process. Alternatively, in a second embodiment, a sheet of fabric or polymeric film having an adhesive lower surface and an opposing outer surface comprising an animal repellant substance is provided. The sheet or film may be applied to the outer surface of a prior art veterinary bandage. The animal repellant is preferably a non-toxic substance.
BACKGROUND: The correlation between body mass index (BMI) and surgical outcomes has emerged as a critical consideration in complex abdominal operations. While elevated BMI is often associated with increased perioperative risk, its specific effects on the outcomes of robotic surgeries remain inadequately explored. This study assesses the impact of BMI on perioperative variables of complex esophageal and hepatopancreaticobiliary (HPB) robotic operations.
METHODS: Following IRB approval, we prospectively followed 607 patients undergoing pancreaticoduodenectomy, trans-hiatal esophagectomy (THE), major liver resection or distal pancreatectomy with splenectomy, all performed robotically. Perioperative data retrieved included operative duration, estimated blood loss (EBL), intraoperative and postoperative complications, conversions to an 'open' operation and length of stay (LOS). Z scores were assigned to each variable to standardize operations, and the variables were then regressed against BMI. For illustrative purposes, data are presented as median(mean ± standard deviation).
RESULTS: Between 2012 and 2020, surgeries included 71 THE, 122 distal pancreatectomies with splenectomies, 129 major hepatectomies and 285 pancreaticoduodenectomies. Median age was 67(65 ± 12.5) years old, and BMI was 27(28 ± 5.5) kg/m2. Operative duration for all operations was 349(355 ± 124.5) min and had a positive correlation with increasing BMI (p = 0.004), specifically for robotic THE and robotic pancreaticoduodenectomy, with both operative durations having positive correlation with increasing BMI (p = 0.02 and p = 0.05). No significant correlation with BMI was found for EBL, intraoperative or postoperative complications, conversion to 'open' surgery, or LOS.
CONCLUSION: Elevated BMI is associated with longer operative durations in select robotic surgeries, such as trans-hiatal esophagectomy and pancreaticoduodenectomy, and highlights the need for strategic planning in these patients.
The purpose of this study is to determine if ecopipam is able to stop urges to gamble in patients diagnosed with Pathological Gambling. Nerves communicate with each other by releasing chemicals called "neurotransmitters". One of these neurotransmitters in the brain is called "dopamine". After dopamine is released by the nerve it "talks" to other nerves by interacting with receptors that are unique to that neurotransmitter. Ecopipam is a drug that selectively blocks one family of dopamine receptors. Some scientists believe that the urge to gamble is related to having too much dopamine in the brain. By blocking the receptors that dopamine uses, ecopipam may be able to relieve the urge to gamble.
FIELD: medicine, pharmaceutics. ^ SUBSTANCE: group of inventions refers to medicine and pharmacology. An agent for treating and preventing diseases associated with stress-related conditions in diseases and disorders in human and animals represents nonapeptide KND by formula as follows: Trp-Lys-Gly-Gly-Asn-Ala-Ser-Gly-Glu, or nonapeptide Trp-Lys-Gly-Gly-Asp-Ala-Ser-Gly-Glu or hexapeptide Trp-Lys-Gly-Gly-Asn-Ala or their pharmaceutically acceptable salts. A pharmaceutical composition for treating and preventing the diseases associated with stress-related conditions in diseases and disorders in human and animals contains nonapeptide KND or nonapeptide Trp-Lys-Gly-Gly-Asp-Ala-Ser-Gly-Glu or hexapeptide Trp-Lys-Gly-Gly-Asn-Ala and glycin and/or a natural antioxidant, particularly, carnosine or homocarnosine. The ingredients of the pharmaceutical composition are related as follows: nonapeptide or hexapeptide: glycin:natural antioxidant makes 1:(10-125):(10-125) by weight. The pharmaceutical composition is used in the form of nasal drops, in the form of spray, powder spray, aerosol, sublingually in the form of lozenge, capsules and powders, in the form of various injections, in the form of suppositories, ointments, creams, lotions. A method of treating and preventing the diseases associated with stress-related conditions in diseases and disorders in human and animals consists in introducing in an organism said pharmaceutical composition 10 mcg/kg to 10 mg/kg at nonapeptide KND or nonapeptide Trp-Lys-Gly-Gly-Asp-Ala-Ser-Gly-Glu or hexapeptide Trp-Lys-Gly-Gly-Asn-Ala. ^ EFFECT: invention provides higher clinical and preventive effectiveness in the diseases associated with stress-related conditions in diseases and disorders in human and animals. ^ 6 cl, 5 tbl